On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Finally, blaming the pharmaceutical industry for high drug costs has historically been PBMs’ go-to defense. In a rebuttal to the FTC report issued in the summer, the PCMA criticized the ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

The FTC’s report details how these PBMs strategically steered patients toward their affiliated pharmacies, where prescription costs often exceeded those at independent pharmacies by more than ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.